Applied Therapeutics, Inc. (APLT)

Applied Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	-0.21	9.99	-	-	-	-
Cost of Revenue	52.35	53.91	55.63	-	-	-
Gross Profit	-52.56	-43.91	-55.63	-	-	-
Selling, General & Admin	39.72	20.62	27.32	43.05	32.68	13.23
Research & Development	-	-	-	62.57	61.79	32.35
Operating Expenses	39.72	20.62	27.32	105.62	94.47	45.58
Operating Income	-92.29	-64.54	-82.95	-105.62	-94.47	-45.58
Interest & Investment Income	2.92	1.37	0.69	0.56	0.56	0.09
Other Non Operating Income (Expenses)	-97.81	-56.57	-0.07	-	-	-
EBT Excluding Unusual Items	-187.17	-119.74	-82.33	-105.06	-93.91	-45.49
Gain (Loss) on Sale of Investments	-0.14	-0.03	-0.18	-0.52	-0.05	-0.02
Pretax Income	-187.31	-119.76	-82.51	-105.58	-93.96	-45.51
Net Income	-187.31	-119.76	-82.51	-105.58	-93.96	-45.51
Net Income to Common	-187.31	-119.76	-82.51	-105.58	-93.96	-45.51
Shares Outstanding (Basic)	131	84	38	26	22	13
Shares Outstanding (Diluted)	131	84	38	26	22	13
Shares Change (YoY)	89.66%	122.72%	47.77%	16.53%	71.19%	134.01%
EPS (Basic)	-1.43	-1.42	-2.18	-4.12	-4.28	-3.55
EPS (Diluted)	-1.43	-1.42	-2.18	-4.12	-4.28	-3.55
Operating Margin	-	-645.80%	-	-	-	-
Profit Margin	-	-1198.47%	-	-	-	-
EBITDA	-92.28	-64.53	-82.95	-105.62	-	-
D&A For EBITDA	0	0	0	0	-	-
EBIT	-92.29	-64.54	-82.95	-105.62	-94.47	-45.58
Revenue as Reported	-	9.99	-	-	-	-

Updated Nov 7, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q